Tag: Zhao-Zhengtuo

3 articles

Policy & Regulation

Chinese Academy of Sciences names brain-computer interfaces a priority field in its 2026 to 2030 plan

The Chinese Academy of Sciences (CAS), China's top state research body, announced on 28 September 2026 that it had released its 15th Five-Year development plan covering 2026 to 2030. The plan lists brain-computer interfaces among its 'important priority fields' (重要优先领域), alongside integrated circuits, artificial intelligence, quantum science and technology, life sciences and biotechnology, and controlled nuclear fusion. CAS will organise research around a '3+4+X' regional layout with Shanghai as one of three strategic highlands, and will explore forming field-based research consortia, mission-based task forces and platform-based facility clusters across its institutes. CAS already runs its own invasive BCI programme: a system developed at its Shanghai Center for Excellence in Brain Science and Intelligence Technology (CEBSIT) was implanted in its first trial participant at Huashan Hospital in March 2025, and StairMed, founded by CEBSIT researcher Zhao Zhengtuo, entered the National Medical Products Administration's innovative device green channel in November 2025 with a market target of around 2028. CAS was one of the seven co-signatories of the 2025 BCI industry implementation opinions. The plan lands six days after Premier Li Qiang inspected BCI products in Shanghai and called future industries a blue ocean for advanced manufacturing. No BCI budget, programme names or milestones have been made public.

Sep 30

Industry News

Chinese endovascular BCI can be positioned in 10 minutes, Xuanwu Hospital surgeon says

Duan Wanru of Xuanwu Hospital in Beijing said an experienced surgeon can position a Chinese endovascular brain-computer interface in as little as 10 minutes. StairMed unveiled a separate endovascular research program in December 2025 with the Chinese Academy of Sciences, currently in sheep testing. Nankai University completed China's first interventional human BCI in June 2025. Three Chinese endovascular BCI programs are now on the public record.

Aug 10

Industry News

StairMed's penetrating BCI trial at Huashan reaches 18 cumulative implants

On 20 July 2026, at the World Artificial Intelligence Conference in Shanghai, StairMed disclosed that its cortex-penetrating invasive BCI clinical trial at Huashan Hospital has now reached 18 cumulative implants since March 2025. The Shanghai firm co-founded by Zhao Zhengtuo and Xue Li at the Chinese Academy of Sciences' Center for Excellence in Brain Science demonstrated a patient three months post-op controlling a wheelchair by thought and hitting 6.19 bits per second on a cursor task, alongside a live journalist test at 4.9 bits per second with a finger.

Jul 20